Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment: A comparative analysis of the literature

Acta Haematologica

Volumn 107, Issue 3, 2002, Pages 158-169

  Vantroyen, B ^a   Vanstraelen, D ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VIRGA JESSE HOSPITAL   (Belgium)

Author keywords

Anagrelide; Aspirin; Blood collection; Essential thrombocythemia; Hydroxyurea; Interferon alpha 2a; Umbilical cord

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2A INTERFERON; ANAGRELIDE; BUSULFAN; DIPYRIDAMOLE; HYDROXYUREA;

ADULT; APHERESIS; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; FEMALE; FETUS DEATH; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; SPONTANEOUS ABORTION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; UMBILICAL CORD BLOOD;

ABORTION, SPONTANEOUS; ASPIRIN; BLOOD COMPONENT REMOVAL; FEMALE; FETAL DEATH; GESTATIONAL AGE; HUMANS; INTERFERON ALFA-2A; PLATELET COUNT; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0036235252     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057634     Document Type: Article

References (64)

1. Essential thrombocythaemia: An interim report from the Polycythemia Vera Study Group
2. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia very by the Thrombocythemia Vera Study Group
3. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies
4. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - Aids to diagnosis and classification
5. Childbearing age patients with essential thrombocythemia: Should they be placed on interferon?
6. Treatment of essential thrombocythemia during pregnancy with interferon-alpha
7. Platelet counts during pregnancy in essential thrombocythaemia treated with recombinant alpha-interferon
8. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia
9. Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon
10. Interferon-alpha-2a treatment in a pregnant woman with essential thrombocythemia
11. Outcome analysis of 34 pregnancies is women with essential thrombocythemia
12. Normal pregnancy in a patient with essential thrombocythemia treated with interferon-alpha-2b
13. Essential thrombocythemia in pregnancy: Platelet count and pregnancy outcome
14. Normal pregnancy and delivery in essential thrombocythemia even without interferon therapy
15. Essential thrombocythemia and pregnancy
16. Primary thrombocythemia and pregnancy: Treatment and outcome in fifteen cases
17. Essential thrombocythemia and pregnancy: A report of six normal pregnancies in five untreated patients
18. Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion
19. Thrombocytémie essentielle et grossesse
20. Essential thrombocythaemia
21. Successful treatment of essential thrombocythemia with alpha interferon during pregnancy
22. Postpartum thrombosis in primary thrombocythaemia
23. Essential thrombocythemia during pregnancy
24. Alpha 2b-interferon therapy and pregnancy: Report of a case of essential thrombocythemia
25. Essential thrombocythemia and complications of pregnancy
26. Familial myeloproliferative syndrome
27. Essential thrombocythemia associated with recurrent abortions and fetal growth retardation
28. Primary thrombocythaemia in pregnancy
29. Essential thrombocythemia and pregnancy
30. Thrombocythaemia and recurrent late abortions: Normal outcome of pregnancies after antiaggregatory treatment: Case report
31. Essential thrombocythemia in pregnancy: A report of two cases
32. Primary thrombocythemia
33. Schwangerschaft bei essentieller thrombozythämie: Manifestationszeitpunkt und risiken für mutter und kind
34. Essential thrombocythemia and pregnancy
35. Pregnancy in women with essential thrombocythaemia
36. Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis
37. Aspirin in essential thrombocythemia: Status quo and quo vadis
38. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy
39. Pregnancy during myelosuppressive treatment for clonic myelogenous leukemia
40. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: A case report
41. Hydroxyurea and pregnancy
42. In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats
43. In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia
44. Recombinant interferon alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis
45. The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia
46. Therapie der thrombozytose bei myeloproliferativen syndromen mit rekombinantem interferon-alpha-2a
47. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a
48. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis
49. Maintenance therapy in the myeloproliferative disorders: The current options
50. Alpha-interferon therapy for essential thrombocythaemia
51. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases
52. Platelet function and interferon alpha-2a treatment in essential thrombocythaemia
53. Low-dose interferon alpha treatment in essential thrombocythemia
54. Experimental study of transplacental passage of alpha interferon by two assay techniques
55. Interferon in human pregnancy
56. Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients
57. Treatment of essential thrombocythaemia by alpha 2a interferon
58. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia
59. Role of anagrelide in the treatment of thrombocytosis
60. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk
61. Clinical annotation: Primary thrombocythaemia: Diagnosis and management
62. No treatment for low-risk thrombocythaemia: Results from a prospective study